Loading...
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
The omega-3 pill Vascepa (icosapent ethyl) — approved to treat very high triglyceride levels — significantly lowered the risk for cardiovascular events in statin-treated patients at high CV risk. Findings from the REDUCE-IT trial were announced by the manufacturer on Monday and will be presented at the American Heart Association's annual meeting in November.
Over 8000 adults with LDL levels controlled on statins, triglyceride levels of 150–499 mg/dL, and either cardiovascular disease or diabetes plus an additional CV risk factor were randomized to take Vascepa (4 g icosapent ethyl daily) or placebo. During roughly 5 years' follow-up, incidence of the primary endpoint — a composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina — was 25% lower with Vascepa. Adverse events were similar in the two groups.
Dr. Harlan Krumholz of NEJM Journal Watch Cardiology commented: "It is important to remember that this is an announcement — there is no presentation, preprint, or paper yet. But the findings are exciting, unexpected, and provocative — and have raised great interest for the release of more information at the AHA Scientific Sessions."
Comment
LINK(S):
Manufacturer's news release (Free)
REDUCE-IT trial details (Free)
Vascepa prescribing information (Free PDF)
Background: Physician's First Watch coverage of FDA allowing marketing of Vascepa for an unapproved use (Free)